Methods for modulating mannose content of recombinant proteins

Patent metadata

Field	Value
Publication number	US-12344668-B2
Application number	US-202017030842-A
Country	US
Kind code	B2
Filing date	Sep 24, 2020
Priority date	Jan 23, 2006
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.

First claim

What is claimed is:

1. A method of treating celiac disease, comprising administering to a subject a composition comprising an antibody or an antigen-binding fragment thereof,
wherein fewer than about 10% of the antibody or antigen-binding fragment molecules in the composition have more than 4 mannose residues per N-linked oligosaccharide, and
wherein the antibody or antigen-binding fragment thereof comprises:
a light chain variable region comprising the CDRs of the light chain variable region sequence set forth in SEQ ID NO:4, and
a heavy chain variable region comprising the CDRs of the heavy chain variable region sequence set forth in SEQ ID NO:2.

2. The method of claim 1 , wherein the composition comprises an antibody or an antigen-binding fragment thereof, wherein the antibody or an antigen-binding fragment thereof comprises:
a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4, and
a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2.

3. The method of claim 1 , wherein the composition comprises an antibody, wherein the antibody comprises:
a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4, and
a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2.

4. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

5. The method of claim 2 , wherein the composition further comprises a pharmaceutically acceptable carrier.

6. The method of claim 3 , wherein the composition further comprises a pharmaceutically acceptable carrier.

Assignees

• Amgen Inc

Inventors

• Wu Jian
• Sabo Nicole
• De La Cruz Michael
• Flynn Gregory

Classifications

• C12N2500/60

  Buffer, e.g. pH regulation, osmotic pressure · CPC title

• C12N2500/12

  Light metals, i.e. alkali, alkaline earth, Be, Al, Mg · CPC title

• C12N5/0037

  Serum-free medium, which may still contain naturally-sourced components · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title